The following is a summary of the Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript:
Financial Performance:
Acumen Pharmaceuticals reported cash and marketable securities worth approximately $297 million at the end of Q1 2024.
R&D expenses for the quarter rose to $12.4 million due to costs related to the ALTITUDE-AD trial.
The company's Q1 G&A expenses increased to $5.3 million due to increased headcount, resulting in an operational loss of $17.8 million for the quarter.
Business Progress:
The first patient has been dosed in the ALTITUDE-AD Phase II study, which trials the effectiveness and safety of sabirnetug.
Positive feedback has been received on the Phase I INTERCEPT results, particularly on patient biomarker improvements.
A Phase I study is planned for a subcutaneous formulation of sabirnetug, which should be launched in mid-2024.
The company has established a collaboration with Lonza for the manufacturing of sabirnetug, leveraging the latter's regulatory knowledge and global manufacturing network.
More details: Acumen Pharmaceuticals IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.